Filters

Pp-163 manufacturers

Filters

None products found

pp-163

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: IDH1 R132-mutant glioma (low-grade glioma and GBM at recurrence) Clinical stage: Phase 2 ongoing Modality: Small molecule Mechanism / Target: Mutant IDH1 (R132H/C/S) inhibitor — blocks neomorphic enzyme activity reducing 2-HG production; allows epigenetic normalisation and differentiation of IDH1-mutant tumour cells; CNS-penetrant design Route / form: Oral tablet Differentiation: CNS penetration designed for glioma (unlike ivosidenib with poor BBB crossing); specifically targets IDH1 R132 mutations prevalent in glioma; potential to delay malignant progression in low-grade glioma
Manufacturer #39189

Oncology company with an FDA-approved ROS1/NTRK inhibitor and next-generation solid tumour pipeline. Focuses on CNS-penetrant kinase inhibitors for molecularly defined lung and other cancers. Wholly owned US/global development with China territory licensed to Innovent Biologics.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.